Last reviewed · How we verify
Ad26.ENVA.01 HIV-1 vaccine
Ad26.ENVA.01 HIV-1 vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 1 development.
At a glance
| Generic name | Ad26.ENVA.01 HIV-1 vaccine |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults (PHASE1)
- A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults (PHASE1)
- Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad26.ENVA.01 HIV-1 vaccine CI brief — competitive landscape report
- Ad26.ENVA.01 HIV-1 vaccine updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Ad26.ENVA.01 HIV-1 vaccine
What is Ad26.ENVA.01 HIV-1 vaccine?
Ad26.ENVA.01 HIV-1 vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID).
Who makes Ad26.ENVA.01 HIV-1 vaccine?
Ad26.ENVA.01 HIV-1 vaccine is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).
What development phase is Ad26.ENVA.01 HIV-1 vaccine in?
Ad26.ENVA.01 HIV-1 vaccine is in Phase 1.